Havana, Jan 25 (Prensa Latina) Cuba is working on a clinical study with the Abdala anti-Covid-19 vaccine in children under two years of age, the Center for Genetic Engineering and Biotechnology (CIGB) reported today.
According to the entity, given the threat that the SARS-CoV-2 virus poses to this population group, it is necessary to work immediately.
The nation, after carrying out a massive immunization campaign for infants over two years of age, does not report deaths in this segment, the principal investigator of clinical trials of the Sovereign 02 vaccine, María Eugenia Toledo, revealed the day before.
«In total, 1.6 million children have been vaccinated in this country with two doses of Soberana 02 plus one of Soberana Plus at an interval of 28 days,» she assured.
In addition to the efforts being made to protect children, the CIGB is focused on demonstrating the safety, immunogenicity and long-term effects of the Mambisa nasal vaccine candidate in the prevention of Covid-19 with the Baconao clinical study.
The center also reported that this immunogen is applied through the nasal route, does not contain thiomersal and induces the generation of antibodies at the mucosal level where the entry point of the pathogen is.
Currently, she added, it is being evaluated in a phase II clinical trial as a booster dose in convalescents.
Precisely during this day, Cuban scientists will present on the development, regulation and deployment of the anti-Covid-19 preparations (Abdala, Soberana 02 and Soberana Plus) of this Caribbean nation, during a virtual event convened by the Progressive International organization.
That organization recently acknowledged that the island has developed its own vaccines, successfully immunized most of its population, and is now poised to help vaccinate the world.
«Their approach is based on two principles: investment in public health and internationalism,» she argued.